<DOC>
	<DOCNO>NCT02893176</DOCNO>
	<brief_summary>Potential therapy MACITENTAN treatment Chronic Lung Allograft Dysfunction ( CLAD ) Lung Transplantation . Pilot Study , Double-blind , `` ADD-ON Therapy '' MACITENTAN `` usual standard care immunosuppressive therapy '' lung transplantation establish BOS Stages I II versus `` matched control group '' receive `` usual standard care immunosuppressive therapy '' alone , result decrease Primary Endpoint : `` rate decline '' `` Forced Expiratory Volume-1 sec ( FEV1 ) versus time '' Secondary Endpoints include : difference Six minute walk distance ( 6MWD ) , BORG Score , correct single-breath diffusing capacity ( DCO correct ) time interval 1 , 3 , 6 month therapy . Specific biomarkers BOS , include inflammatory chemokines , routinely collect context post-transplant `` surveillance '' analyze . Chemokines group previously describe pathogenesis continuum `` acute-to-chronic lung allograft rejection '' , include C-C ( CCL2 , CCL5 ) CXC ( CXCL9 , CXCL10 , CXCL11 ) chemokines determine bronchial-alveolar lavage ( BAL ) .</brief_summary>
	<brief_title>Macitentan Treatment Organ Rejection After Lung Transplantation</brief_title>
	<detailed_description>Preliminary study employ `` rat tracheal allograft transplant model '' demonstrate amelioration fibrous airway obliteration associate blockade renin-angiotension endothelin system implement ERA antagonist , BOSENTAN ( 100 mg/kg ) . Clinical study indeed demonstrate mitogenic profibrotic peptide , ET-1 , may represent potential biomarker clinical BOS . Detection level ET-1 mRNA significantly increase lung allograft versus without BOS 3 12 month post-transplantation ET-1 concentration significantly elevate serum bronchoalveolar lavage fluid ( BALF ) patient BOS . Additional study demonstrate pronounced inhibitory effect elicit chronic ET ( A ) receptor blockade absence immunosuppressive therapy , plasma level transcriptional regulation inflammatory chemokines rat heterotopic heart transplant model chronic rejection . MACITENTAN , novel , competitive ERA significantly slow receptor dissociation kinetics currently approve ERAs , may represent renew hope patient suffer progressive CLAD post-transplantation . The efficacy MACITENTAN realize exploratory Phase II MUSIC Trial IPF primary endpoint measure force vital capacity ( FVC ) , nevertheless , mechanistic disparity pathobiology CLAD versus IPF , therefore preclude separate therapeutic trial . Further , vitro treatment MACITENTAN major metabolite ( ACT-132577 ) decrease alpha smooth muscle actin elaboration dermal fibroblast systemic sclerosis fibrotic skin lesion , therefore offer significant promise potential disease modulation . Most importantly , MUSIC Trial demonstrate `` clinical safety '' pharmacologic therapy 178 patient IPF mean drug exposure approximately 14 month without statistical difference incidence abnormal liver function study . Recent pharmacokinetic study MACITENTAN suggest `` clinically significant '' drug-drug interaction respect Cytochrome P4503A4 concurrent post-transplant immunosuppressive type therapy , cyclosporine , tacrolimus mycophenolate mofetil ; insignificant interaction frequently implement `` azole-type antibiotic '' also observe .</detailed_description>
	<mesh_term>Macitentan</mesh_term>
	<criteria>UCLA unilateral bilateral lung transplant recipient , age : 2165 year . Females child bearing age could become pregnant , must implement appropriate contraception per FDA requirement `` ERA medical treatment '' mandatory MONTHLY monitoring urine serum pregnancy test . No concurrent clinically significant chronic liver disease Screening echocardiogram ( perform usual posttransplant standard care ) LVEF &gt; 40 % , `` Grade I '' le `` LV diastolic dysfunction '' . Nonintubated , fully ambulatory patient perform respiratory maneuver office Spirometry DCO 6MWD ( tracheostomy ) . Total 20 patient BOS Stage I II , randomize doubleblind 'standard care + placebo '' versus `` standard care + MACITENTAN '' Groups . Laboratory `` safety study '' already routinely monitor context posttransplant patient ' chronic immunosuppressive regimen include : comprehensive metabolic panel , tacrolimus trough level , Btype natriuretic peptide ( BNP ) , CBC + platelet count . `` Physiologic '' outcomes study already consider `` standard care '' lung transplant recipient include : Officebased Spirometry pre postbronchodilator , correct DCO , six minute walk distance + BORG score assessment ( 6MWD ) interval 13 month routine Lung Transplant Clinic followup appointment . UCLA unilateral bilateral lung transplant recipient , age : 65 year age . Females child bearing age could become pregnant , refuse implement appropriate contraception per FDA requirement `` ERA medical treatment '' mandatory MONTHLY monitoring urine serum pregnancy test become pregnant . Concurrent clinically significant chronic liver disease Intubated patient Patients perform respiratory maneuver office Spirometry DCO 6MWD ( tracheostomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lung Transplant</keyword>
	<keyword>Macitentan</keyword>
	<keyword>CLAD</keyword>
	<keyword>BOS</keyword>
	<keyword>bronchiolitis obliterans</keyword>
	<keyword>chronic lung allograft dysfunction</keyword>
	<keyword>Organ Rejection</keyword>
</DOC>